Study finds few COVID-19 patients get rebound symptoms after Paxlovid treatment
Scientists discover and characterize a novel membraneless organelle that could play a role in Alzheimer’s treatment
14 June 2022EU buys 110,000 vaccine doses against monkeypox
14 June 2022Study finds few COVID-19 patients get rebound symptoms after Paxlovid treatment
Mayo Clinic researchers studied the outcomes of 483 high-risk patients treated for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, together marketed as Paxlovid. Only a handful developed COVID-19 rebound symptoms, and the researchers say more studies are needed to determine why.
